Menu
Home//Products//Development Pipeline//Pipeline Overview

Pipeline Overview*

Pipeline Overview*

Drug2 Indication Pre-clinical Phase i/ii Phase iii Marketed
TALICIA® (RHB-105) H. pylori infections
Confirmatory Phase III study ongoing
RHB-104 Crohn's disease
Positive top-line results from Phase III MAP US study
RHB-204 NTM infections
Pivotal Phase III study planned
BEKINDA®
(RHB-102)		 Gastroenteritis & gastritis
Positive results from Phase III U.S. study
IBS-D
Positive results from Phase II U.S. study
RHB-106 Bowel cleanser
WW rights licensed to Salix Pharmaceuticals
YELIVA® (ABC294640) Multiple indications
Cholangiocarcinoma and other indications
RHB-107 (MESUPRON) Oncology/GI
Completed multiple clinical studies
Other
 RIZAPORT®
(RHB-103)		 Migraine
U.S. NDA filed - re-submission of NDA planned following CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies 2 BEKINDA®, YELIVA® and TALICIA® are proposed tradenames which are subject to FDA review and approval
Commercial Products Development Pipeline Pipeline Overview TALICIA® (H. pylori) RHB-104 (GI/Inflammation) RHB-204 (NTM) BEKINDA® (GI) RHB-106 (GI) YELIVA® (Oncology) RHB-107 (Oncology/GI) Expanded Access Program

Recent News

SEE ALL NEWS
 
Home | Site Map
Copyright © 2017 RedHill. All Rights Reserved. Created by Catom web design | SEO
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok
Thank you for visiting RedHill's website at www.redhillbio.com ("RedHill Site"). By clicking "OK", you acknowledge and understand that you will be linked outside of the RedHill Site and into other independent third party websites ("Third Party Sites"). You further acknowledge and agree that we have no control over the Third Party Sites nor over any content contained therein. You further acknowledge that we are not responsible in any way for the availability, suitability, accuracy and completeness of any information or links contained in any of the Third Party Sites, nor do we endorse, or are we responsible or liable for, any services, content, advertisements, products or any materials on, or available from or through, any of the Third Party Sites. In addition, we urge you to carefully review each of the Third Party Sites' terms of service and privacy policies, if such exist, before visiting such Third Party Sites. Ok